Overexpression of VEGF and angiopoietin 2: A key to high vascularity of hepatocellular carcinoma?

Modern Pathology

Volumn 16, Issue 6, 2003, Pages 552-557

  Moon, Woo Sung ^a   Rhyu, Ki Hoon ^a   Kang, Myoung Jae ^a   Lee, Dong Geun ^a   Yu, Hee Chul ^a   Yeum, Jung Ho ^a   Koh, Gou Young ^b   Tarnawski, Andrzej S ^c,d  

^a Chonbuk National University   (South Korea)

^b Pohang University of Science and Technology (POSTECH)   (South Korea)

^c VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Angiopoietin; Hepatocellular carcinoma; p53; Vascular endothelial growth factor

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; MESSENGER RNA; PROTEIN P53; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

ADULT; AGED; ANGIOPOIETIN-2; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION; LIVER NEOPLASMS; MALE; MICROCIRCULATION; MIDDLE AGED; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; RETROSPECTIVE STUDIES; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0038118504     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000071841.17900.69     Document Type: Article

References (30)

1. Yeh CN, Lee WC, Jeng LB, Chen MF, Yu MC. Spontaneous tumor rupture and prognosis in patients with hepatocellular carcinoma. Br J Surg 2002;89:1125-9.
2. Leung DW, Carchianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.
3. Fox SB, Garter KC, Harris AL. Tumor angiogenesis. J Pathol 1996;179:232-7.
4. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25.
5. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryogenic angiogenesis. Cell 1996;87:1171-80.
6. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand S, Radziejewski C, et al. Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science 1997;277:55-80.
7. Valenzuela DM, Griffiths J, Rojas J, Aldrich TH, Jones PF, Zhou H, et al. Angiopoietin 3 and 4: diverging gene counterparts in mouse and man. Proc Natl Acad Sci U S A 1999;96:4-9.
8. Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre PC, Yancopoulos GD, Sessa WC. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 1999;79:213-23.
9. Kwak HJ, So JN, Lee SJ, Kim I, Koh GY. Angiopoietin-1 is an apoptosis survival factor for endothelial cells. FEBS Lett 1999;448:249-53.
10. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, et al. Vessel co-option, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994-8.
11. Lauren J, Gunji Y, Alitalo K. Is angiopoietin-2 necessary for the initiation of tumor angiogenesis? Am J Pathol 1998;153:1333-9.
12. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutation in human cancers. Science 1991;253:49-53.
13. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, Cleary K, et al. Mutation in the p53 gene occur in diverse human tumor types. Nature 1989;342:705-8.
14. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:346-55.
15. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994;255:989-91.
16. Kimura H, Nakajima T, Kagawa K, Deguchi T, Kakusui M, Katagishi T, et al. Angiogenesis in hepatocellular carcinoma as evaluated by CD34 immunohistochemistry. Liver 1998;18:14-9.
17. Dumont DJ, Gradwohl G, Fong GH, Puri MC, Gerenstein M, Auerbach A, et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. Genes Dev 1994;8:1897-909.
18. Bunone G, Vigneri P, Mariani L, Buto S, Collini P, Pilotti S, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999;155:1967-76.
19. Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol 1998;153:1459-66.
20. Tanaka S, Mori M, Sakamoto Y, Makuuchi MN, Sugimachi K, Wands JR. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest 1999;103:341-5.
21. Hayes AJ, Huang WQ, Yu J, Maisonpierre PC, Liu A, Kern FG, et al. Expression and function of angiopoietin-1 in breast cancer. Br J Cancer 2000;83:1154-60.
22. Ahmad SA, Liu W, Jung YD, Fan F, Willson M, Reinmuth N, et al. The effects of angiopoietin-1 and -2 on tumor growth and angiogenesis in human colon cancer. Cancer Res 2001;61:1255-9.
23. Takahama M, Tsutsumi M, Tsujiuchi T, Vezu K, Kushibe K, Taniguchi S, et al. Enhanced expression of Tie2, its ligand angiopoietin-1 vascular endothelial growth factor, and CD31 in human non-small cell lung carcinoma. Clin Cancer Res 1999;5:2506-10.
24. Shim WSN, The M, Mack POP, Ge R. Inhibition of angiopoietin-1 expression in tumor cells by an antiserum RNA approach inhibited xenograft tumor growth in immunodeficient mice. Int J Cancer 2001;94:6-15.
25. Uchida S, Shimada Y, Watanabe H, Tanaka H, Shibagaki I, Miyahara T, et al. In esophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br J Cancer 1998;77:1704-9.
26. Linderholm BK, Lindahl T, Holmberg L, Klaar S, Lennerstrand J, Henriksson R, Bergh J. The expression of vascular endothelial growth factor correlates with mutant p53 and poor prognosis in human breast cancer. Cancer Res 2001;61:2256-60.
27. Strohmeyer D, Rossing C, Bauerfeind A, Kaufmann O, Schlechte H, Bartsch G, et al. Vascular endothelial growth factor and its correlation with angiogenesis and p53 expression in prostatic cancer. Prostate 2000;45:216-24.
28. Kawahara N, Ono M, Taguchi K, Okamoto M, Shimada M, Takenaka K, et al. Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma. Hepatology 1998;28:1512-27.
29. Ng IO, Fan ST. Is the p53 mutation of prognostic value in hepatocellular carcinoma [letter]? Arch Surg 2000;135:1476.
30. El-Assal ON, Yamanoi A, Soda Y, Yamaguchi M, Igarashi M, Yamamoto A, et al. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998;27:1554-62.